← Back to headlines
Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN)
Truist has reaffirmed its "Buy" rating for Viridian Therapeutics (VRDN), indicating continued confidence in the company's stock performance.
26 Apr, 15:13 — 26 Apr, 15:13
Sources
Showing 1 of 1 sources
